FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.